Compare VTIX & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTIX | OKYO |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.9M | 87.6M |
| IPO Year | 2025 | 2021 |
| Metric | VTIX | OKYO |
|---|---|---|
| Price | $1.13 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | ★ 340.9K | 63.6K |
| Earning Date | 08-11-2026 | 07-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,252,643.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.44 | N/A |
| 52 Week Low | $1.13 | $1.34 |
| 52 Week High | $9.00 | $3.20 |
| Indicator | VTIX | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 29.57 | 41.85 |
| Support Level | N/A | N/A |
| Resistance Level | $1.41 | $1.72 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 3.23 | 21.43 |
Virtuix Holdings Inc pioneers movement in AI-generated worlds, both imaginary and real. The company is the creator of Omni, a brand of omni-directional treadmills that enable users to walk and run in 360 degrees inside virtual reality (VR) games, digital twins, and other applications. Its technology operates at the intersection of gaming, fitness, and enterprise VR. Its products include Omni Pro, Omni Arena, and Omni One. Its business integrates a consumer and enterprise VR hardware platform anchored by its flagship Omni One product with a defense-oriented simulation system, Virtual Terrain Walk (VTW), targeting next-generation immersive mission planning.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.